Controlled clinical trial of adjuvant immunotherapy with BCG and neuraminidase-treated autologous tumour cells in large bowel cancer

J Surg Oncol. 1989 Jan;40(1):34-7. doi: 10.1002/jso.2930400109.

Abstract

A controlled, randomised clinical trial of immunotherapy was performed in 301 patients with stage B or C colorectal cancer. The immunotherapy treatment consisted of 18 vaccinations over a 2 year period following surgery with a combination of BCG given by scarification plus subcutaneous injection of Vibrio cholera neuraminidase (VCN)-modified autologous tumour cells. Five year follow-up has now been completed in all patients. The immunotherapy did not alter either the disease-free interval or the overall survival of patients in comparison with a control group of patients not receiving immunotherapy.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adenocarcinoma / mortality
  • Adenocarcinoma / radiotherapy
  • Adenocarcinoma / therapy*
  • BCG Vaccine / therapeutic use*
  • Clinical Trials as Topic
  • Colorectal Neoplasms / mortality
  • Colorectal Neoplasms / surgery
  • Colorectal Neoplasms / therapy*
  • Combined Modality Therapy
  • Follow-Up Studies
  • Humans
  • Immunotherapy*
  • Neoplasm Metastasis
  • Neuraminidase / therapeutic use*
  • Random Allocation
  • Vibrio cholerae

Substances

  • BCG Vaccine
  • Neuraminidase